Stocklytics Platform
Asset logo for symbol BMY
Bristol-Myers Squibb Co
BMY61
$56.85arrow_drop_down0.97%-$0.56
S&P500
Asset logo for symbol BMY
BMY61

$56.85

arrow_drop_down0.97%
Key Stats
Open$57.46
Prev. Close$57.42
EPS-4.41
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range56.19
57.91
52 Week Range39.35
62.22
Ratios
EPS-4.41
Fundamentals
Payout Ratio-
Industry average yield3.27%
Last Dividend pay dateFeb 3, 2025
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

BMY-
US Healthcare Sector-
US Market-
warning

BMY / Market

BMY lose to the US Market which returned -0.68% over the last twenty four hours.
warning

BMY / Healthcare Sector

BMY lose to the US Healthcare sector which returned 1.01% over the last twenty four hours.

Bristol-Myers Squibb Co (BMY) Statistics

Bristol-Myers Squibb Co (BMY) is a leading pharmaceutical company that specializes in the development and production of innovative medicines. As of the latest statistics, BMY stock is performing well in the market. It has a strong valuation, supported by its solid fundamentals. The company's revenue per share has been consistently increasing, indicating its growth potential. BMY's enterprise to EBITDA ratio is also favorable, suggesting its ability to generate substantial earnings relative to its debt. Additionally, BMY has a healthy profit margin, showcasing its efficient management of costs and operations. Although the company carries a considerable amount of total debt, its strong gross profit ensures its ability to meet financial obligations. Overall, BMY's stock performance has been steady and resilient, consistently outperforming its sector.
The CEO of Bristol-Myers Squibb Co, a key figure in the company's success, plays a crucial role in steering the organization towards growth and profitability. Their strategic decision-making and vision are instrumental in driving innovation and maintaining a competitive edge. With a dedicated leadership team, led by the CEO, BMY is well-positioned to capitalize on opportunities in the pharmaceutical industry. The company's commitment to research and development, along with its strong pipeline of potential treatments, enables it to address unmet medical needs and improve patient outcomes. Bristol-Myers Squibb Co's dedication to scientific excellence and patient-centric approach has made it a trusted name in the healthcare sector.
add Bristol-Myers Squibb Co to watchlist

Keep an eye on Bristol-Myers Squibb Co

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Bristol-Myers Squibb Co (BMY) stock's performance compared to its sector and the market over the past year?

Over the past year, Bristol-Myers Squibb Co (BMY) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 18.46%, Bristol-Myers Squibb Co has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 44.54%, it has fallen short of the market average. This comparison highlights Bristol-Myers Squibb Co's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Bristol-Myers Squibb Co (BMY) stock?

The PE ratio for Bristol-Myers Squibb Co (BMY) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Bristol-Myers Squibb Co (BMY) stock?

The Earnings Per Share (EPS) for Bristol-Myers Squibb Co (BMY), calculated on a diluted basis, is -$4.41. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Bristol-Myers Squibb Co (BMY) stock?

The operating margin for Bristol-Myers Squibb Co (BMY) is 18.48%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Bristol-Myers Squibb Co (BMY) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Bristol-Myers Squibb Co (BMY) is $18.41B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Bristol-Myers Squibb Co (BMY) have?

Bristol-Myers Squibb Co (BMY) has a total debt of $51.44B. The net debt, which accounts for cash and cash equivalents against the total debt, is $43.51B.

Take Your Investments to a Whole New Level